Literature DB >> 6172066

UCLA conference. Interferon: immunobiology and clinical significance.

E R Stiehm, L H Kronenberg, H M Rosenblatt, Y Bryson, T C Merigan.   

Abstract

Interferons are proteins elaborated by infected cells that protect noninfected cells from viral infection. These proteins produce a temporary "antiviral state" by altering nucleotide metabolism and cytoplasmic enzyme induction. Interferons appear early after viral infection locally and systematically to limit spread of viral infection; they also affect cell differentiation, growth, surface, antigen expression, morphologic findings, and immunoregulation. Several human disorders have diminished interferon production. Newborns have normal interferon alpha but deficient interferon gamma production. Infants with congenital infections may also have defects in interferon production. Immunosuppressed patients receiving transplants (marrow, heart, of kidney) have diminished interferon production, particularly immediately after transplant. Deficiencies of interferon have also been noted in Down's syndrome, cellular immunodeficiencies, uremia, malnutrition, and hematopoietic malignancy. Leukocyte interferon has been of therapeutic value in herpes zoster infections, in patients with cancer, and in patients with hepatitis B infection. Interferon has not been proved to help children with congenital cytomegalovirus or rubella. Interferon can shrink lymphoid tumors, particularly non-Hodgkin's lymphoma.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6172066     DOI: 10.7326/0003-4819-96-1-80

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  16 in total

Review 1.  Interferons 1992. How much of the promise has been realised?

Authors:  M A Volz; C H Kirkpatrick
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

2.  Treatment of early stage-B chronic lymphocytic leukemia with alpha-2b interferon after chlorambucil reduction of the tumoral mass.

Authors:  E Montserrat; N Villamor; A Urbano-Ispizua; J M Ribera; M Lozano; J L Vives-Corrons; C Rozman
Journal:  Ann Hematol       Date:  1991-07       Impact factor: 3.673

3.  Histamine releasing factor is not an interferon.

Authors:  I C Ezeamuzie; E S Assem
Journal:  Agents Actions       Date:  1986-04

Review 4.  Viewpoint on the impact of interferon in the treatment of multiple myeloma: benefit for a small proportion of patients?

Authors:  J Bladé; J Esteve
Journal:  Med Oncol       Date:  2000-05       Impact factor: 3.064

5.  Downregulation of interferon alpha but not gamma receptor expression in vivo in the acquired immunodeficiency syndrome.

Authors:  A S Lau; S E Read; B R Williams
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

Review 6.  Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis.

Authors:  D E Goodkin
Journal:  West J Med       Date:  1994-09

7.  Remissions in newly diagnosed type 1 (insulin-dependent) diabetes: influence of interferon as an adjunct to insulin therapy.

Authors:  V A Koivisto; A Aro; K Cantell; M Haataja; J Huttunen; S L Karonen; P Mustajoki; R Pelkonen; P Seppälä
Journal:  Diabetologia       Date:  1984-08       Impact factor: 10.122

8.  Interferon in the prevention of genital herpes recurrence.

Authors:  L J Eron; L Harvey; C Toy; D Santomauro
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

9.  Kaposi's sarcoma in AIDS patients: long-term treatment with recombinant interferon alpha-2a and chemotherapy.

Authors:  M Flepp; M G Täuber; R Lüthy; W Siegenthaler
Journal:  Klin Wochenschr       Date:  1988-05-16

10.  Interferon gamma production by human intestinal mucosal mononuclear cells. Decreased levels in inflammatory bowel disease.

Authors:  B Y Lieberman; C Fiocchi; K R Youngman; W K Sapatnekar; M R Proffitt
Journal:  Dig Dis Sci       Date:  1988-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.